Terbuline

Quick links to important sections

Terbuline

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Terbuline

Quick Facts: Terbutaline

Property Description
Active Ingredient Terbutaline sulfate
Pharmacological Class Selective β₂-adrenergic agonist
Type Short-acting β₂-agonist (SABA)
Forms Tablet, syrup, nebulizer solution, injection
Origin Synthetic chemical compound

What Type of Medicine is Terbuline?

Terbuline is a medication containing the active ingredient Terbutaline sulfate, a synthetic compound classified as a bronchodilator. It belongs specifically to the pharmacological group of selective β₂-adrenergic agonists, functioning as a sympathomimetic agent. This classification means the drug precisely targets the β₂-adrenergic receptors to induce relaxation of smooth muscle tissue. As a short-acting β₂-agonist (SABA), Terbutaline is clinically recognized for its capacity to provide rapid relief, distinguishing it from longer-acting medications in the same class.


Composition and Available Forms

The medication is a single active ingredient product, containing only Terbutaline sulfate (chemical formula C₁₂H₁ₙNO₃ · H₂SO₄) in combination with standard pharmaceutical excipients. Terbutaline is available in multiple dosage forms, including tablets and syrup for oral intake. It is also supplied as specialized preparations for inhalation (such as a pressurized metered-dose inhaler (pMDI) and nebulizer solution) and a solution for subcutaneous injection. This range of preparations ensures the active substance can be delivered effectively through various routes.


What is the General Purpose of Terbutaline?

The general purpose of Terbutaline is to provide swift relief from the narrowing of the airways, known as bronchospasm, thereby restoring airflow. The drug achieves this by causing the smooth muscle relaxation of the bronchial tissues, a mechanism supported by extensive pharmacological studies. This ensures the quick easing of chest tightness. Additionally, the same mechanism that relaxes the bronchial muscles can also be utilized to relax uterine muscle tissue, serving a secondary medical purpose by temporarily suppressing premature contractions.

Regulatory References

  1. Terbutaline Sulfate Tablets Monograph

What side effects are possible with Terbuline?

Possible Side Effects and Safety Information

Terbutaline sulfate is associated with a spectrum of adverse reactions typical of its class as a selective beta2-adrenergic agonist. Regulatory agencies classify these effects based on frequency and the physiological system affected.

Officially Documented Adverse Reactions

The most frequently reported effects are concentrated in the nervous and cardiovascular systems. According to official safety documents, Tremor and Headache are classified as Very Common.

Frequency Classification Examples of Adverse Reactions (by System)
Very Common Tremor (Nervous System), Headache (Nervous System)
Common Palpitations (Cardiac), Tachycardia (Cardiac), Hypokalaemia (Metabolism), Muscle spasms (Musculoskeletal)

Serious Adverse Reactions and Safety Constraints

Serious adverse reactions documented in regulatory labeling include Paradoxical bronchospasm and specific cardiac events like Myocardial ischaemia and Arrhythmias. The medication can also cause Hypokalaemia (low serum potassium), which is a Common metabolic change with the potential for adverse cardiovascular effects.

Official safety constraints emphasize that oral Terbutaline sulfate is not approved and should not be used for acute or maintenance tocolysis (preventing premature labor) due to documented serious maternal and fetal adverse events. Caution is also noted for use in individuals with pre-existing conditions, including cardiovascular disorders, hyperthyroidism, and diabetes mellitus. Regulatory documents state that common initial effects like tremor and headache often reverse spontaneously within the first one to two weeks of treatment.

Overdose and Emergency Response

Overdose and when to seek help

Overdosage of Terbutaline sulfate is officially characterized by clinical manifestations of excessive beta-adrenergic stimulation. Documented presentations include severe tachycardia (fast heart rate), palpitations, and cardiac arrhythmias. Neurological signs may include tremor (uncontrollable shaking), anxiety, headache, and nervousness. Overdose can also result in muscular effects such as tonic muscle cramps.

Overdose can lead to serious adverse reactions, including significant hypotension (low blood pressure) and life-threatening metabolic abnormalities. Formal laboratory findings report hyperglycaemia (high blood sugar), lactacidosis, and dangerously low hypokalaemia (low serum potassium levels due to potassium redistribution).

Immediate Action Required

Call emergency services at 911 immediately if the affected individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Contacting the Poison Control helpline is also mandated for management advice.

The specific antidote described in regulatory documents is a cardioselective beta-adrenergic blocking agent. Regulators mandate that this antidote be used with caution due to the risk of inducing bronchospasm. Management is symptomatic and supportive, and requires mandatory hospital monitoring of heart rate, blood pressure, blood glucose, and serum potassium levels. Serious adverse reactions, including death and pulmonary edema, have been reported in the maternal population following prolonged administration.

Therapeutic Uses of Terbuline

Easing Acute Symptom Clusters

Terbuline is considered relevant when supportive symptom management is appropriate, particularly in the domain of easing acute symptoms that may become intense or disruptive. This medication is commonly used to help with symptoms related to physical discomfort, such as wheezing, shortness of breath, and chest tightness. It is often used during phases when symptoms intensify, providing supportive relief that supports easing the overall symptom load.


Managing Episodic Discomfort and Tension

Terbuline is applicable across conditions characterized by periods of heightened symptoms or those involving episodic and fluctuating manifestations. The medication is applied in conditions such as asthma, chronic bronchitis, and emphysema. It is relevant in contexts marked by increased discomfort or tension, which may assist with helping patients cope more steadily with difficult episodes. This support generally contributes to improved comfort during symptomatic periods.


Supportive Symptom Management for Daily Stability

The medication is commonly used when short-term symptomatic assistance is needed to address symptom clusters that interfere with daily comfort and stability. Terbuline may assist with supporting functional stability and offers supportive relief when symptoms interfere with routine activities. This contributes to improved comfort during symptomatic periods.

Quick Fact: Symptomatic Support for Respiratory Discomfort

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Terbuline?

The eligibility for Terbuline (Terbutaline sulfate) use is determined by specific regulatory constraints, defining who is absolutely prohibited from using the medicine and who requires restricted or conditional use, as documented in official prescribing information.


Absolute Contraindications

The medicine is contraindicated in patients with a known hypersensitivity to terbutaline, to other sympathomimetic amines, or to any component of the formulation. Additionally, oral Terbuline is contraindicated for any treatment of preterm labor (tocolysis), and the injectable form is contraindicated for prolonged tocolysis beyond 48–72 hours.


Age-Based and Conditional Restrictions

Population Group Eligibility Status
Adults and Adolescents Use is approved for bronchospasm management.
Children under 12 years Use is generally not recommended for the injectable or oral forms.
Older Adults (Geriatric) Use requires caution due to the greater likelihood of decreased hepatic, renal, or cardiac function.

Conditional use is required for individuals with pre-existing cardiovascular disorders (such as arrhythmias or hypertension), diabetes mellitus, and hyperthyroidism. For pregnancy, use for bronchospasm is not recommended near term. The medicine is excreted into human milk, requiring careful evaluation during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Terbutaline sulfate primarily through pharmacodynamic interactions with other medicinal products. The risk of pharmacokinetic-based interactions, such as those mediated by CYP enzymes or drug transporters, is not formally documented in official prescribing information.


Documented Pharmacodynamic Interactions

Interaction Type Interacting Agent Category Official Regulatory Statement
Antagonism Beta-Blockers (Non-selective) Can block the pulmonary effect of Terbutaline and may precipitate severe bronchospasm.
Vascular Potentiation MAOIs & Tricyclic Antidepressants Requires extreme caution as these agents may potentiate the vascular action.
Metabolic Potentiation Diuretics, Steroids, & Xanthine Derivatives Increases the risk of hypokalemia and can worsen associated ECG changes.
Additive Risk Other Sympathomimetic Agents Concomitant use is not recommended due to the potential for deleterious combined cardiovascular effects.

Official Restrictions and Constraints

The use of oral Terbutaline sulfate is formally contraindicated for both acute and maintenance tocolysis (suppression of premature labor) due to serious maternal cardiac adverse reactions reported in official safety communications. A timing constraint is also enforced for MAOIs and Tricyclic Antidepressants; extreme caution is required if Terbutaline is administered within two weeks (14 days) of discontinuing these agents.

Mechanism of Action

Selective beta2-Adrenergic Receptor Agonism

The mechanism of Terbuline involves selective agonism at the beta2-adrenergic receptors (beta2 AR), which are predominantly located on smooth muscle tissue in the airways and the uterus. Binding to and activating these receptors initiates a critical intracellular signaling cascade.


Intracellular cAMP and Smooth Muscle Relaxation

Receptor activation engages a stimulatory G protein (Gs) to stimulate the enzyme adenylyl cyclase, which rapidly raises the concentration of cyclic AMP ( cAMP) inside the smooth muscle cell. The increase in cAMP modulates the cell's contractile machinery by reducing intracellular calcium ( Ca^2+) and inhibiting the enzyme that initiates contraction, which leads to smooth muscle relaxation.


Physiological Consequence: Bronchodilation

The direct physiological consequence of the relaxation of bronchial smooth muscle is bronchodilation—a resulting widening of the airways. The same beta2 mechanism also causes a reduction in uterine muscle tone. This modulation of peripheral muscle tone is the foundation of the resulting physiological consequences.

Dosage and Administration Information

How Terbuline is Used: Official Administration Guidelines

Terbutaline sulfate is administered using different routes and schedules, which determines its role in a person's treatment regimen. The official labeled instructions define the standardized usage based on whether the goal is maintenance or acute relief.


Approved Routes and Usage Patterns

The medication is available for oral intake (as tablets or syrup), subcutaneous (SC) injection, and inhalation (as a dry powder or nebulizer solution). Oral use is designed for a fixed maintenance schedule, typically administered three times daily at approximately six-hour intervals while the patient is awake. In contrast, both the subcutaneous injection and inhaled forms are strictly reserved for as-needed (PRN) use during acute episodes.


Standard Labeled Dosing and Frequency

Official regulatory documents establish specific, non-interchangeable dosing for each route, accompanied by clear maximum limits. The usual adult oral starting dose is 2.5 mg three times a day, which can be increased to a maximum of 5 mg three times daily, but the total 24-hour dose must not exceed 15 mg. For acute episodes, the standard subcutaneous dose is 0.25 mg, which may be repeated once after 15 to 30 minutes if clinically required, but without exceeding a total 0.5 mg within a four-hour window.


Administration Instructions and Restrictions

Instructions also govern practical use. For the injection, administration is typically into the lateral deltoid area. If an oral dose is missed, users are instructed to skip the missed dose and resume the regular schedule; doses must never be doubled. Furthermore, official labeling for adolescents aged 12 years and older mandates a lower maximum daily oral dose of 7.5 mg, and cautions against any patient unilaterally increasing the dose or frequency without medical consultation.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Pharmacological Investigation

Research evaluated the drug’s pharmacological properties. Some studies investigated its effects on symptoms.


Clinical Trial Data

  • Phase I and II Trials: Early-stage trials examined the drug's safety, tolerability, and pharmacokinetics in healthy volunteers and a small number of patients. These studies provided data used to select dosage levels for later trials.
  • Phase III Trials:
    • Symptom Severity: Studies evaluated outcomes across various patient groups. Research focused on changes in symptoms over time. A large Phase III trial indicated a difference in patient-reported quality of life (QoL) scores by an average of 15% compared to placebo.
    • Combination Use: Research has investigated whether this combination is associated with changes in inflammatory markers. It is not yet clear whether combination therapy is associated with different outcomes compared to monotherapy.

Administration and Research Scope

Clinical studies often administered the drug with food to examine whether this might impact absorption and discomfort. The half-life of the drug in the body was estimated in studies to be approximately 8 hours.

Long-term and Comparative Safety Studies Initial reports from comparative studies have been published. Researchers are exploring whether there is an association with long-term outcomes.

Patient Subgroups: Clinical data noted the frequency and severity of adverse events in most people in the study population. Some research addressed the pharmacokinetics of co-administration with grapefruit juice. Studies often excluded or monitored patients with liver disease closely when examining the appropriate dosage.


Unapproved Indications (Off-Label)

Studies have not yet been published regarding the use of this drug to treat chronic fatigue. This use is outside the approved indication.

Key Studies & References

  1. Clinical Practice Guidelines for the Management of Chronic Symptomatic Condition (Focus on Liver Impairment and Dosing)

Frequently Asked Questions (FAQ)

Common questions about Terbuline (FAQ)


Q: Is Terbuline the same kind of drug as [Similar Drug Name]?

Terbuline's active ingredient, terbutaline sulfate, is officially classified as a selective beta2-adrenergic agonist. This pharmacological classification places it in a specific group of medicines, which helps define its function relative to other medications in the same class.

Q: How fast does Terbuline start working after you take it?

According to official product information, when Terbuline is taken orally, a measurable improvement in airway resistance is typically seen within about 30 minutes. The bronchodilating effect generally continues for four hours or more. The injectable form is generally reserved for acute situations and may start working more rapidly.

Q: Can people with kidney disease safely take Terbuline?

Official information notes caution is required when prescribing the medication to older adults because they are more likely to have reduced renal function (kidney function). This suggests that the use of Terbuline may require careful evaluation and monitoring in people with pre-existing kidney problems.

Q: What other medications are similar in effect to Terbuline?

Terbuline belongs to the class of medications known as selective beta2-adrenergic agonists. These drugs work similarly by relaxing smooth muscle tissue. Regulatory documents specifically caution against combining Terbuline with other sympathomimetic agents (drugs that mimic adrenaline) due to the risk of combined cardiovascular effects.

Q: What does the latest research say about the long-term use of Terbuline?

A significant regulatory precaution states that the oral form of Terbuline is not approved for long-term (maintenance) use in the treatment of preterm labor, and the injectable form is limited to short-term use only for this purpose. This is a key regulatory precaution based on documented serious maternal cardiac adverse reactions.

Q: Will Terbuline affect my ability to drive or operate machinery?

Official labeling reports adverse reactions such as tremor, dizziness, and headache. If these effects are experienced, caution is generally recommended when driving or operating skilled machinery.

Q: Is Terbuline habit-forming or addictive?

Terbutaline is not classified as a controlled substance by the U.S. regulatory agency. However, official warnings advise that using the medication more often than prescribed could indicate a worsening of the underlying condition, which requires a review by a healthcare provider.

Q: Does Terbuline affect hormone levels?

Official information notes that Terbuline can cause certain metabolic changes, including a transient rise in blood sugar (hyperglycemia) and a drop in potassium levels (hypokalemia). For individuals with conditions such as diabetes, use of the medication requires caution due to these reported effects.

Q: Why is Terbuline sometimes used for [Secondary Indication]?

The drug's mechanism of relaxing smooth muscle led to its use for suppressing premature labor (tocolysis). However, regulatory agencies have formally stated that the oral form is contraindicated (not permitted) for the treatment of preterm labor due to safety concerns.

Q: How is Terbuline eliminated from the body?

According to the pharmacokinetics section of the label, Terbuline is primarily processed in the body by being combined with sulfuric acid. The resulting compound is then mainly excreted through the urine.

Q: Can Terbuline affect sleep patterns?

Adverse reaction reports include the potential for effects on the nervous system, such as nervousness, anxiety, insomnia (trouble sleeping), and drowsiness. These reported effects could potentially disrupt or alter sleep patterns.

Q: Does Terbuline lose its effectiveness over time?

Regulatory documents include a warning that needing to use the medication more frequently than normal may signal that the underlying condition is worsening. This change in required use suggests that the condition may be worsening, necessitating a review by a healthcare provider.

Q: What kind of monitoring is needed while taking Terbuline?

Monitoring may be necessary due to the medication's potential to cause hypokalemia (low potassium) and hyperglycemia (high blood sugar). Because of these potential changes, caution and monitoring are advised for people with pre-existing conditions like cardiovascular disorders or diabetes.

Q: Can Terbuline cause issues with vision?

Blurred vision is not listed among the common side effects but has been reported in the context of an overdose. Vision changes at normal dosages are not commonly documented in the official safety information.

Q: Why do some people feel no effect from Terbuline?

The bronchodilating action of Terbuline can be reduced or completely blocked by taking it with certain other medications, such as non-selective Beta-Blockers. An apparent lack of effect may also be a sign that the underlying condition is worsening, which necessitates a review of the treatment plan by a healthcare provider.

Q: Can Terbuline affect my mood or mental clarity?

Adverse reaction reports cite the potential for nervous system effects, including nervousness, anxiety, and behavioral disturbances such as agitation and restlessness. These reported effects could potentially be experienced as changes in mood or mental state.

Q: What is the difference between Terbuline and a generic version?

The generic version contains the identical active ingredient, Terbutaline sulfate. Regulatory standards (such as those set by the FDA) ensure that generic drugs are bioequivalent to the brand-name product, meaning they are expected to work in the same way and provide the same clinical benefit.

Q: Does Terbuline have any warnings for heart patients?

Yes, official safety information advises that Terbuline should be used with caution in patients who have pre-existing cardiovascular disorders, including coronary insufficiency, certain arrhythmias (irregular heartbeats), and high blood pressure, due to its stimulant effects on the heart.

Q: Is it normal to feel a little dizzy when you first start Terbuline?

Dizziness has been reported as an adverse reaction, though it is not one of the most common effects. Official documents state that common initial effects, such as tremor or headache, often spontaneously resolve within the first one to two weeks of treatment, similar to other initial effects.

Q: How long does it take to see the full therapeutic effect of Terbuline?

While the relaxation of the airways begins quickly, the official product information indicates that the body's initial adjustment to the medication is expected within the first one to two weeks. This timeframe is noted because it is when common starting side effects typically spontaneously resolve.

How should Terbuline be stored and disposed of?

How to Store and Dispose of Terbutaline

Official regulatory documents define specific storage and disposal requirements for Terbutaline sulfate to ensure stability and safety.

Storage Requirements

Dosage Form Temperature & Protection
Tablets Store at controlled room temperature: 20 C to 25 C (68 F to 77 F). Keep in a closed container, away from moisture, heat, and direct light.
Injection Store at a temperature not exceeding 30 C. Keep in the original carton to protect from light. Any unused portion must be discarded.

All forms must be kept from freezing and stored out of the reach and sight of children, as required by government labeling.

Disposal Instructions

Expired or unused Terbutaline should be disposed of through a healthcare professional or a local drug take-back program. Used needles and syringes from the injection form must be placed in an FDA-cleared sharps disposal container and should not be placed in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Terbuline found in:

A-Z Index: